NASDAQ · BDSX
Biodesix, Inc.
$24.72+$1.86 (+8.14%)
Biodesix, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.68% below the high.
Loading market information…
NASDAQ · PETS · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
PetMed Express, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.22% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
PetMed Express, Inc.’s forward annual dividend is $1.20 per share, paid quarterly. The forward yield is 101.69% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
PetMed Express, Inc.’s next earnings report is currently expected on Nov 10, 2026, with estimated earnings per share of -$0.11. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow PetMed Express, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
PetMed Express, Inc., through its various subsidiaries, operates as a prominent pet pharmacy across the United States. The company provides a comprehensive range of both prescribed and over-the-counter animal medications, health-related items, and other essential supplies for canines, felines, and equines. Their non-prescription offerings include products for flea and tick prevention, joint and bone care, vitamins, treats, nutritional supplements, hygiene essentials, and general pet supplies. For prescription needs, they supply heartworm and flea/tick preventatives, alongside medications for conditions such as arthritis, dermatitis, thyroid imbalances, diabetes, pain relief, and cardiovascular issues, often providing generic alternatives. Beyond pharmaceuticals, the company also retails pet food, bedding, crates, stairs, and various other accessories. PetMed Express engages with its clientele through multiple distribution channels: its official website, a dedicated mobile application, a telephone contact center, direct mail campaigns (like brochures and postcards), and television advertisements, frequently promoting its 1-800-PetMeds and PetMeds brands. The company was established in 1996 and is headquartered in Delray Beach, Florida.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:02 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2026 | Aug 26, 2025 | -$0.49-716.67% vs estimate | $51.10M-26.27% vs estimate |
|---|
| Q3 2025 | Feb 10, 2025 | -$0.03-700.0% vs estimate | $52.98M-1.88% vs estimate |
|---|
| Q2 2025 | Nov 6, 2024 | $0.11+320.0% vs estimate | $59.57M-9.74% vs estimate |
|---|
THE ANALYST VIEW
10 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $1.40.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$24.72+$1.86 (+8.14%)
Biodesix, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.68% below the high.
$2.00+$0.04 (+2.04%)
Fortress Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.85% below the high.
$0.73+$0.01 (+1.67%)
Rein Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
$1.57+$0.01 (+0.64%)
Spectral AI, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.14% below the high.
$0.92-$0.06 (-5.74%)
TELA Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.67% below the high.
$2.98+$0.01 (+0.34%)
111, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.32% below the high.
$4.40-$0.84 (-16.03%)
Cytosorbents Corporation’s quoted price sits in the lower half of its reported 52-week range, 74.12% below the high.
$0.62+$0.02 (+2.48%)
Genenta Science S.p.A.’s quoted price sits in the lower half of its reported 52-week range, 80.32% below the high.
